Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.

Background: Extra-intestinal manifestations (EIMs) can impact morbidity in patients with inflammatory bowel diseases (IBD; Crohn's disease [CD] and ulcerative colitis [UC]). This study compared incidence rates of EIMs in patients with moderate to severe IBD receiving gut-selective vedolizumab (VDZ)...

Descripción completa

Detalles Bibliográficos

Publicado en:	Inflammatory Bowel Diseases Vol. 24; no. 9; pp. 1876 - 1883
Autores principales:	Dubinsky, Marla C., Cross, Raymond K., Sandborn, William J., Long, Millie, Xue Song, Nianwen Shi, Yao Ding, Eichner, Samantha, Pappalardo, Brandee, Ganguli, Arijit, Wang, Anthony
Formato:	research tables/charts Journal Article
Publicado:	Oxford University Press / USA Sep2018
Acceso en línea:	Ver este registro en EBSCOhost